Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2025-04-25 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：关于续聘2025年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the audit firm for the fiscal year 2025. It details the qualifications, integrity, and independence of the audit firm, as well as the procedures followed by the audit committee, board of directors, and supervisory board to approve the reappointment. The document does not contain any financial statements or audit reports themselves, but rather is a formal notice about the selection and continuation of the audit firm. The document length is 3319 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of an Audit Report / Information announcement about the audit firm appointment, not the audit report itself. Hence, the appropriate classification is AR (Audit Report / Information). FY 2025
2025-04-25 Chinese
赛伦生物：关于召开2024年度暨2025年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an investor earnings explanation meeting (业绩说明会) for the 2024 annual results and 2025 first quarter results. It provides details on the meeting time, location, participants, and how investors can participate and ask questions. It does not contain actual financial statements or detailed financial analysis but rather informs about the upcoming event where such information will be discussed. The document length is short (1578 characters) and it is clearly an announcement of a meeting rather than the meeting transcript or the financial report itself. Therefore, it fits best into the category of Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials, strategy, and market position, specifically an earnings explanation meeting.
2025-04-21 Chinese
赛伦生物：关于审计机构变更项目质量控制复核人的公告
Audit Report / Information Classification · 95% confidence The document is an announcement from Shanghai SAILUN Biotechnology Co., Ltd. regarding a change in the project quality control reviewer at the audit firm Tianzhi International for the company's 2024 annual audit. It details the replacement of the original reviewer with a new individual, including their background, disciplinary records, and independence statement. The document does not contain financial statements or audit results but is an announcement about a change related to the audit process. It references the audit firm and the 2024 annual audit but is not the audit report itself. The document length is 1872 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit quality control personnel changes and audit-related information, but is not a full annual report or certification. Confidence is high due to the clear focus on audit quality control personnel change and related disclosures. FY 2024
2025-04-08 Chinese
赛伦生物：关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai SAILUN Biotech Co., Ltd. regarding the use of temporarily idle raised funds for cash management. It details the board and supervisory committee approvals, the amount and purpose of the cash management, risk controls, and regulatory compliance. The document references regulatory guidelines and approvals but does not contain financial statements or detailed financial results. It is a formal disclosure about the company's financing activities related to the use of raised funds, specifically about cash management of idle funds. This fits the definition of a Capital/Financing Update (CAP) as it updates on the company's use of fundraising proceeds and capital management activities. The document length is 3601 characters, which is relatively short but contains substantive information about capital use rather than just announcing a report publication or certification. Therefore, the best classification is CAP with high confidence.
2025-03-20 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor (方正证券承销保荐有限责任公司) regarding the use of temporarily idle raised funds by Shanghai Sailun Biotechnology Co., Ltd. for cash management. It references regulatory rules related to the management and use of raised funds, details the amount, purpose, risk control measures, and approval procedures by the board and supervisory committee. The document is not a financial report, earnings release, or audit report but rather a regulatory compliance and verification statement related to fundraising and fund usage. It is not a brief announcement but a formal verification opinion. This fits best under Regulatory Filings (RNS) as it is a compliance-related document that does not fit other specific categories like Capital/Financing Update or Audit Report.
2025-03-20 Chinese
赛伦生物：2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, net income, and other key financial metrics. The data is explicitly stated as preliminary and unaudited, with a disclaimer that the final audited data will be disclosed in the company's 2024 Annual Report. The document is relatively short (1806 characters) and serves as an initial announcement of financial results rather than a full detailed report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. Therefore, the correct classification is Earnings Release (ER). FY 2024
2025-02-25 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.